Welcome to our dedicated page for Zentek news (Ticker: ZTEK), a resource for investors and traders seeking the latest updates and insights on Zentek stock.
Zentek Ltd. (ZTEK) generates news across several advanced technology domains, reflecting its role as an intellectual property development and commercialization company. Its disclosures highlight activity in graphene-based coatings, critical mineral development, aptamer-based healthcare technologies and fire-retardant materials, giving investors and observers multiple streams of company-specific updates.
A major news theme is Zentek’s work through its wholly owned subsidiary Albany Graphite Corp. on the Albany Graphite Project in Ontario. Recent releases describe ultra-high purity Albany graphite reaching five-nines carbon purity with an Equivalent Boron Concentration below thresholds generally referenced for nuclear applications, as well as additional nuclear suitability testing and independent verification using near-net-shaped graphite bricks. Separate announcements cover lithium-ion battery suitability testing, where spheroidized Albany graphite has shown near-theoretical anode performance under industry-standard conditions.
Another recurring topic is Zentek’s ZenGUARD™ platform for surgical masks and HVAC air filters, including corporate updates on testing under the Government of Canada’s Innovative Solutions Canada program and efforts to advance ZenGUARD™ Enhanced Air Filters in Canada and international markets. News items also address the company’s development of a Graphite Gel-Based Fire-Retardant product and an exclusive licensing arrangement with Altek Advanced Materials Inc. for commercialization in the United States.
Healthcare-focused news includes progress on multivalent aptamer countermeasures against influenza through Triera Biosciences and McMaster University, supported by a federal testing contract. Corporate governance and capital markets developments, such as CEO transitions, board appointments, annual meeting voting results and tax reassessment matters, are reported through regular press releases and associated Form 6-K filings. Readers following ZTEK news can expect updates on technology milestones, regulatory and testing programs, strategic partnerships and key corporate decisions.
Zentek (NASDAQ: ZTEK) engaged ICP Securities to provide automated market-making using its proprietary ICP Premium® algorithm, effective April 1, 2026. The agreement has an Initial Term of four months with automatic monthly renewals and a monthly fee of C$7,500 plus taxes. The engagement is subject to TSX Venture Exchange approval.
The arrangement includes no equity or performance-based pay, allows ICP and its clients to acquire securities, and aims to improve liquidity and quote quality for shareholders.
Triera Biosciences (NASDAQ:ZTEK) is launching contract research organization services for custom aptamer discovery, biosensor enablement, and ML classification support on March 25, 2026.
Built on an exclusive 20-year McMaster University license, Triera offers integrated SELEX aptamer development, biosensor integration, and optional ML signal classification targeting infectious disease and oncology diagnostics across North America and Europe.
Zentek (NASDAQ:ZTEK) won a favorable judgment in Ontario Superior Court on March 12, 2026, dismissing substantially all claims in companion litigation tied to the 2018 removal of founder Aubrey Eveleigh.
The Court denied monetary claims originally exceeding $6 million, refused cancellation of 4.5 million founder shares, and found relevant statements factually accurate.
Zentek (NASDAQ:ZTEK) provided a PDAC 2026 update covering government and First Nations engagement during the March 1-4 convention in Toronto. The company attended the TSX Canadian Mining Roundtable on March 2, held meetings with federal and provincial representatives and Invest Ontario, and advanced collaboration with Constance Lake First Nation for the Albany Graphite Project.
Zentek said discussions advanced Albany's positioning for critical-minerals funding frameworks and planning toward environmental baseline studies and a new Preliminary Economic Assessment.
Zentek (NASDAQ:ZTEK) initiated an 8–12 week pilot evaluation with Quality Filters to test integration of Zentek's proprietary air filtration media into Quality's commercial HVAC and industrial filter lines. The pilot will assess compatibility, manufacturing scalability, and real‑world performance as a step toward a potential long‑term supply or licensing arrangement.
The pilot supports Zentek's IP‑integration commercialization pathway and runs in parallel with U.S. regulatory evaluation and an existing royalty arrangement with Altek.
Zentek (NASDAQ:ZTEK) outlines government engagement and plans to advance the Albany Graphite Project toward a Pre-Feasibility Study (PFS). Key actions include commissioning a new Preliminary Economic Assessment this fiscal quarter, initiating second-year environmental baseline work, advancing FBR purification engineering, and pursuing non-dilutive federal and provincial funding.
Albany has laboratory-scale nuclear-grade results (99.9992% purity; 2.60 ppm boron) and is positioned to access programs such as Canada's $2-billion Strategic Resource Fund and Ontario's $500 million Critical Minerals Processing Fund.
Zentek (NASDAQ: ZTEK) was granted a 180‑day extension to regain compliance with Nasdaq's $1.00 minimum bid price rule, extending the cure period to August 24, 2026. The company must maintain a closing bid of at least $1.00 for ten consecutive business days on or before that date. There is no immediate effect on listing or trading; shares will continue to trade under ZTEK. Management says it will monitor the bid price and consider available options to regain compliance.
Zentek (NASDAQ:ZTEK) outlined a strategic reset focused on three core platforms: Albany Graphite, ZenGUARD and Triera, with milestone-based capital allocation, cost reductions, and pause of non-core work.
Key technical news: independent labs show Albany graphite can reach 5N (99.9992%) purity with 2.60 ppm boron, meeting the sub-3 ppm nuclear threshold. Near-term steps include an updated PEA, pilot-scale processing, environmental baseline work with Constance Lake First Nation, and options to spin out or partner within 12–18 months. Health Canada currently treats ZenGUARD Enhanced Air Filters as pest control products, and Zentek continues to submit data and evaluate label or market options.
Zentek (NASDAQ: ZTEK) announced a strategic reset on January 29, 2026, narrowing focus to three core platforms: Albany Graphite, ZenGUARD, and Triera, each managed to defined milestones with a 24-month roadmap.
The company said it will pause non-core initiatives, reduce costs via workforce and facility optimization, tighten corporate spending, and link future capital raises to specific milestones. The Chief Science Officer, Colin van der Kuur, has departed and responsibilities were redistributed across technical leadership. Zentek said it will increase segment-level disclosure and milestone tracking.
Zentek (Nasdaq:ZTEK) said subsidiary Albany Graphite achieved ultra-high purity—five‑nines (99.9992%) with an equivalent boron concentration of 2.60 ppm—meeting the <3 ppm threshold commonly referenced for nuclear applications. Independent lab tests of near‑net‑shaped graphite bricks confirmed finished components met key nuclear‑grade benchmarks for strength, density, electrical performance and impurity levels.
Management cites a growing ultra‑high‑purity graphite market (estimated 10.5% CAGR to 2030) and projects potential demand of 100,000–200,000 tonnes/year of purified natural high‑purity graphite over 15–20 years, positioning Albany as a potential North American supplier for nuclear, defense, aerospace and premium battery markets.